We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+16.92%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$856M
AUM Growth
-$46.4M
(-5.1%)
Cap. Flow
-$173M
Cap. Flow
% of AUM
-20.16%
Top 10 Holdings %
Top 10 Hldgs %
41.76%
Holding
72
New
17
Increased
18
Reduced
27
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$40.9M |
| 2 |
Novartis
NVS
|
+$35.1M |
| 3 |
Teva Pharmaceuticals
TEVA
|
+$25.7M |
| 4 |
Viatris
VTRS
|
+$24.6M |
| 5 |
Edwards Lifesciences
EW
|
+$18.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$53.6M |
| 2 |
Cigna
CI
|
+$28.3M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$26M |
| 4 |
AET
Aetna Inc
AET
|
+$22.6M |
| 5 |
Biogen
BIIB
|
+$20.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.17% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Merck
MRK
$307B
| $45.8M | 5.35% |
755,589
-264,987
| -26% | -$16.1M |
|
|
2
Johnson & Johnson
JNJ
$599B
| $42.6M | 4.98% |
+342,350
| New | +$40.9M |
|
3
Pfizer
PFE
$141B
| $39.3M | 4.59% |
1,211,438
-648,180
| -35% | -$20.4M |
|
4
Neurocrine Biosciences
NBIX
$17.4B
| $36.8M | 4.3% |
851,019
+102,031
| +14% | +$4.37M |
|
|
5
Novartis
NVS
$285B
| $35.1M | 4.1% |
+527,082
| New | +$35.1M |
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $33.9M | 3.95% |
272,066
-161,915
| -37% | -$19.4M |
|
|
ABMD
7
DELISTED
Abiomed Inc
ABMD
| $32.8M | 3.83% |
261,691
+10,275
| +4% | +$1.19M |
|
|
FOLD
8
DELISTED
Amicus Therapeutics
FOLD
| $30.7M | 3.59% |
4,311,696
-788,502
| -15% | -$4.99M |
|
9
DexCom
DXCM
$29.2B
| $30.3M | 3.54% |
1,429,364
-609,980
| -30% | -$11.9M |
|
|
SHPG
10
DELISTED
Shire pic
SHPG
| $30.3M | 3.53% |
173,679
+15,521
| +10% | +$2.71M |
|
11
Acadia Healthcare
ACHC
$3.17B
| $30.1M | 3.52% |
691,010
-195,395
| -22% | -$7.93M |
|
|
NUVA
12
DELISTED
NuVasive, Inc.
NUVA
| $29.3M | 3.42% |
391,989
-106,700
| -21% | -$7.74M |
|
13
BioMarin Pharmaceuticals
BMRN
$11.4B
| $27.7M | 3.23% |
315,233
-176,867
| -36% | -$15.7M |
|
14
Teladoc Health
TDOC
$1.74B
| $26.5M | 3.09% |
1,058,553
-511,325
| -33% | -$10.6M |
|
|
15
Teva Pharmaceuticals
TEVA
$36.1B
| $24.2M | 2.83% |
+753,821
| New | +$25.7M |
|
|
16
Viatris
VTRS
$19.8B
| $23.8M | 2.78% |
+610,743
| New | +$24.6M |
|
|
PTLA
17
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $23.7M | 2.76% |
604,041
-815,363
| -57% | -$26M |
|
18
Acadia Pharmaceuticals
ACAD
$4.3B
| $23.1M | 2.69% |
671,113
-505,430
| -43% | -$17.8M |
|
19
Intuitive Surgical
ISRG
$125B
| $22M | 2.57% |
258,048
-123,696
| -32% | -$9.77M |
|
|
20
Edwards Lifesciences
EW
$48.9B
| $18.9M | 2.2% |
+601,437
| New | +$18.8M |
|
|
WMGI
21
DELISTED
Wright Medical Group Inc
WMGI
| $18.1M | 2.11% |
581,222
+122,245
| +27% | +$3.32M |
|
|
AERI
22
DELISTED
Aerie Pharmaceuticals
AERI
| $17.7M | 2.06% |
389,423
+154,125
| +66% | +$6.87M |
|
|
KTWO
23
DELISTED
K2M Group Holdings, Inc
KTWO
| $17.2M | 2% |
836,520
+681,070
| +438% | +$14M |
|
|
ALDR
24
DELISTED
Alder Biopharmaceuticals
ALDR
| $14.8M | 1.73% |
713,119
+43,768
| +7% | +$969K |
|
|
NXTM
25
DELISTED
NxStage Medical Inc.
NXTM
| $13.5M | 1.58% |
504,568
-386,745
| -43% | -$10.7M |
|
Similar funds
RIP
CCM
LFWA
FWA
CF
WIM
MW
AFC
Sectoral Asset Management's Q1 2017 Portfolio in Review
As of Q1 2017, Sectoral Asset Management held 72 positions worth $856M, down 5.1% from $903M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Sectoral Asset Management withdrew a net $173M in Q1 2017, closing 7 positions and reducing 27 holdings. Its most notable exit was Eli Lilly, an estimated $53.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 90% a quarter earlier, followed by Financials.
Against the trend, Sectoral Asset Management opened a new position in Johnson & Johnson worth $42.6M.
- Sectoral Asset Management's largest Q1 2017 buy was Johnson & Johnson: 342,350 shares worth $42.6M.
- Sectoral Asset Management added most to K2M Group Holdings, Inc in Q1 2017, an estimated $14M increase.
- Sectoral Asset Management's biggest Q1 2017 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $26M.
- Sectoral Asset Management fully exited Eli Lilly in Q1 2017, selling an estimated $53.6M.
- Sectoral Asset Management's ten largest holdings make up 42% of its $856M portfolio in Q1 2017.
- Sectoral Asset Management opened 17 new positions and closed 7 in Q1 2017.
- Sectoral Asset Management's portfolio value fell 5.1% quarter-over-quarter to $856M.
Based on Sectoral Asset Management's 13F filing for Q1 2017, filed 15 May 2017.